The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Prostatic Hyperplasia

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Prostatic Hyperplasia


Psychiatry related information on Prostatic Hyperplasia


High impact information on Prostatic Hyperplasia


Chemical compound and disease context of Prostatic Hyperplasia


Biological context of Prostatic Hyperplasia


Anatomical context of Prostatic Hyperplasia


Gene context of Prostatic Hyperplasia

  • These findings suggest that ligands specific for ERbeta may be useful in the prevention and/or clinical management of prostatic hyperplasia and neoplasia [27].
  • Hey1 colocalizes with AR in the epithelia of patients with benign prostatic hyperplasia, where it is found in both the cytoplasm and the nucleus [28].
  • We found that although DAX-1 is expressed in normal human prostate, its expression is strongly reduced in benign prostatic hyperplasia suggesting that DAX-1 plays a role in limiting AR activity in prostate [29].
  • In the present study, we investigated by use of 35S-labeled antisense RNA probes whether the MCP-1 gene is expressed in tissue specimens of benign prostatic hyperplasia (n = 13) and specimens of prostate carcinoma (n = 8), both of which are characterized by a prominent fibromuscular stroma and inconspicuous inflammatory infiltrates [30].
  • Telomerase, a ribonucleoprotein, is detected in the vast majority of prostate cancer, but not in normal or benign prostatic hyperplasia tissues [31].

Analytical, diagnostic and therapeutic context of Prostatic Hyperplasia


  1. Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Shen, R., Su, Z.Z., Olsson, C.A., Fisher, P.B. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  2. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues. Camiolo, S.M., Markus, G., Englander, L.S., Siuta, M.R., Hobika, G.H., Kohga, S. Cancer Res. (1984) [Pubmed]
  3. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Girinsky, T., Koumenis, C., Graeber, T.G., Peehl, D.M., Giaccia, A.J. Cancer Res. (1995) [Pubmed]
  4. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Hamdy, F.C., Autzen, P., Robinson, M.C., Horne, C.H., Neal, D.E., Robson, C.N. Cancer Res. (1997) [Pubmed]
  5. Heightened interferon-gamma production by mononuclear cells from bladder cancer patients. Shapiro, A., Ratliff, T.L., Kelley, D.R., Catalona, W.J. Cancer Res. (1984) [Pubmed]
  6. The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. Raskind, M.A., Dobie, D.J., Kanter, E.D., Petrie, E.C., Thompson, C.E., Peskind, E.R. The Journal of clinical psychiatry. (2000) [Pubmed]
  7. Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. Lacey, J.V., Deng, J., Dosemeci, M., Gao, Y.T., Mostofi, F.K., Sesterhenn, I.A., Xie, T., Hsing, A.W. International journal of epidemiology. (2001) [Pubmed]
  8. Unsafe and potentially safe herbal therapies. Klepser, T.B., Klepser, M.E. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. (1999) [Pubmed]
  9. Terazosin, finasteride, or both in benign prostatic hyperplasia. Thien, T., Lenders, J.W. N. Engl. J. Med. (1997) [Pubmed]
  10. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Lepor, H., Williford, W.O., Barry, M.J., Brawer, M.K., Dixon, C.M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., Padley, R.J. N. Engl. J. Med. (1996) [Pubmed]
  11. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. Gormley, G.J., Stoner, E., Bruskewitz, R.C., Imperato-McGinley, J., Walsh, P.C., McConnell, J.D., Andriole, G.L., Geller, J., Bracken, B.R., Tenover, J.S. N. Engl. J. Med. (1992) [Pubmed]
  12. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S., Redwine, E. N. Engl. J. Med. (1987) [Pubmed]
  13. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. Peters, C.A., Walsh, P.C. N. Engl. J. Med. (1987) [Pubmed]
  14. Indomethacin and symptomatic relief of benign prostatic hyperplasia. Presti, J.C. JAMA (1995) [Pubmed]
  15. Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol. Moore, R.J., Gazak, J.M., Wilson, J.D. J. Clin. Invest. (1979) [Pubmed]
  16. Concentration of dihydrotestosterone and 3 alpha-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog. Moore, R.J., Gazak, J.M., Quebbeman, J.F., Wilson, J.D. J. Clin. Invest. (1979) [Pubmed]
  17. Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration. Naber, K.G., Sörgel, F., Kees, F., Jaehde, U., Schumacher, H. Am. J. Med. (1989) [Pubmed]
  18. Altered metabolism of androgens in elderly men with benign prostatic hyperplasia. Ishimaru, T., Pages, L., Horton, R. J. Clin. Endocrinol. Metab. (1977) [Pubmed]
  19. Trans-differentiation of prostatic stromal cells leads to decreased glycoprotein hormone alpha production. Rumpold, H., Mascher, K., Untergasser, G., Plas, E., Hermann, M., Berger, P. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  20. Interplay between sex steroids and melatonin in regulation of human benign prostate epithelial cell growth. Gilad, E., Matzkin, H., Zisapel, N. J. Clin. Endocrinol. Metab. (1997) [Pubmed]
  21. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Guan, M., Zhou, X., Soulitzis, N., Spandidos, D.A., Popescu, N.C. Clin. Cancer Res. (2006) [Pubmed]
  22. The induction of prostatic hypertrophy in the dog with androstanediol. Walsh, P.C., Wilson, J.D. J. Clin. Invest. (1976) [Pubmed]
  23. Gamma-aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism. Azuma, H., Inamoto, T., Sakamoto, T., Kiyama, S., Ubai, T., Shinohara, Y., Maemura, K., Tsuji, M., Segawa, N., Masuda, H., Takahara, K., Katsuoka, Y., Watanabe, M. Cancer Res. (2003) [Pubmed]
  24. Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Mutaguchi, K., Yasumoto, H., Mita, K., Matsubara, A., Shiina, H., Igawa, M., Dahiya, R., Usui, T. Cancer Res. (2003) [Pubmed]
  25. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Sakko, A.J., Ricciardelli, C., Mayne, K., Tilley, W.D., Lebaron, R.G., Horsfall, D.J. Cancer Res. (2001) [Pubmed]
  26. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. De Marzo, A.M., Meeker, A.K., Epstein, J.I., Coffey, D.S. Am. J. Pathol. (1998) [Pubmed]
  27. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Weihua, Z., Makela, S., Andersson, L.C., Salmi, S., Saji, S., Webster, J.I., Jensen, E.V., Nilsson, S., Warner, M., Gustafsson, J.A. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  28. Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Belandia, B., Powell, S.M., García-Pedrero, J.M., Walker, M.M., Bevan, C.L., Parker, M.G. Mol. Cell. Biol. (2005) [Pubmed]
  29. Repressors of androgen and progesterone receptor action. Agoulnik, I.U., Krause, W.C., Bingman, W.E., Rahman, H.T., Amrikachi, M., Ayala, G.E., Weigel, N.L. J. Biol. Chem. (2003) [Pubmed]
  30. Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Mazzucchelli, L., Loetscher, P., Kappeler, A., Uguccioni, M., Baggiolini, M., Laissue, J.A., Mueller, C. Am. J. Pathol. (1996) [Pubmed]
  31. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Kondo, Y., Koga, S., Komata, T., Kondo, S. Oncogene (2000) [Pubmed]
  32. Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue. Eklöv, S., Funa, K., Nordgren, H., Olofsson, A., Kanzaki, T., Miyazono, K., Nilsson, S. Cancer Res. (1993) [Pubmed]
  33. Comparison of intravenous ciprofloxacin and intravenous cefotaxime for antimicrobial prophylaxis in transurethral surgery. Cox, C.E. Am. J. Med. (1989) [Pubmed]
  34. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Hermani, A., Hess, J., De Servi, B., Medunjanin, S., Grobholz, R., Trojan, L., Angel, P., Mayer, D. Clin. Cancer Res. (2005) [Pubmed]
  35. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Mohler, J.L., Chen, Y., Hamil, K., Hall, S.H., Cidlowski, J.A., Wilson, E.M., French, F.S., Sar, M. Clin. Cancer Res. (1996) [Pubmed]
  36. In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Bartholdi, M.F., Wu, J.M., Pu, H., Troncoso, P., Eden, P.A., Feldman, R.I. Int. J. Cancer (1998) [Pubmed]
WikiGenes - Universities